AAAAAA

   
Results: 1-25 | 26-50 |
Results: 26-50/50
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies
Authors: Ahmad, S Jeske, WP Walenga, JM Hoppensteadt, DA Wood, JJ Herbert, JM Messmore, HL Fareed, J
Citation: S. Ahmad et al., Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies, CL APPL T-H, 5(4), 1999, pp. 259-266
Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors
Authors: Haas, S Walenga, JM Jeske, WP Fareed, J
Citation: S. Haas et al., Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors, CL APPL T-H, 5(1), 1999, pp. 52-59
Clinical and applied thrombosis/ hemostasis - Foreword
Authors: Haas, S Walenga, JM
Citation: S. Haas et Jm. Walenga, Clinical and applied thrombosis/ hemostasis - Foreword, CL APPL T-H, 5, 1999, pp. S1-S1
Inadequacy of current prevention strategies for heparin-induced thrombocytopenia
Authors: Wallis, DE Lewis, BE Messmore, HL Pifarre, R Walenga, JM
Citation: De. Wallis et al., Inadequacy of current prevention strategies for heparin-induced thrombocytopenia, CL APPL T-H, 5, 1999, pp. S16-S20
Laboratory diagnosis of heparin-induced thrombocytopenia
Authors: Walenga, JM Jeske, WP Fasanella, AR Wood, JJ Ahmad, S Bakhos, M
Citation: Jm. Walenga et al., Laboratory diagnosis of heparin-induced thrombocytopenia, CL APPL T-H, 5, 1999, pp. S21-S27
Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome
Authors: Ahmad, S Walenga, JM Jeske, WP Cella, G Fareed, J
Citation: S. Ahmad et al., Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome, CL APPL T-H, 5, 1999, pp. S32-S37
Soluble adhesion molecules in the HIT syndrome: Pathophysiologic role and therapeutic modulation
Authors: Fareed, J Walenga, JM Hoppensteadt, DA Jeske, WP Ahmad, S Lietz, H McKenna, R Messmore, HL Haas, S
Citation: J. Fareed et al., Soluble adhesion molecules in the HIT syndrome: Pathophysiologic role and therapeutic modulation, CL APPL T-H, 5, 1999, pp. S38-S44
Antithrombin agents: The new class of anticoagulant and antithrombotic drugs
Authors: Fareed, J Lewis, BE Callas, DD Hoppensteadt, DA Walenga, JM Bick, RL
Citation: J. Fareed et al., Antithrombin agents: The new class of anticoagulant and antithrombotic drugs, CL APPL T-H, 5, 1999, pp. S45-S55
Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents
Authors: Jeske, WP Jay, AM Haas, S Walenga, JM
Citation: Wp. Jeske et al., Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents, CL APPL T-H, 5, 1999, pp. S56-S62
Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome
Authors: Walenga, JM Michal, K Hoppensteadt, D Wood, JJ Robinson, JA Bick, RL
Citation: Jm. Walenga et al., Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome, CL APPL T-H, 5, 1999, pp. S76-S84
Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood
Authors: Kaiser, B Jeske, W Walenga, JM Fareed, J
Citation: B. Kaiser et al., Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood, BL COAG FIB, 10(8), 1999, pp. 495-501
Hemostatic effects of 1 mg daily warfarin on post CABG patients
Authors: Walenga, JM Hoppensteadt, D Pifarre, R Cressman, MD Hunninghake, DB Fox, NL Terrin, ML Probstfield, JL
Citation: Jm. Walenga et al., Hemostatic effects of 1 mg daily warfarin on post CABG patients, J THROMB TH, 7(3), 1999, pp. 313-318
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using High Performance Liquid Chromatography and functional methods
Authors: Ahmad, S Iqbal, O Ahsan, A Hoppensteadt, DA Lewis, BE Walenga, JM Fareed, J
Citation: S. Ahmad et al., Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using High Performance Liquid Chromatography and functional methods, INT ANGIOL, 18(3), 1999, pp. 198-205
Heparin-induced thrombocytopenia - Preface
Authors: Walenga, JM Messmore, HL Fareed, H
Citation: Jm. Walenga et al., Heparin-induced thrombocytopenia - Preface, SEM THROMB, 25, 1999, pp. 1-1
Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: A clinician's perspective
Authors: Wallis, DE Lewis, BE Walenga, JM
Citation: De. Wallis et al., Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: A clinician's perspective, SEM THROMB, 25, 1999, pp. 3-7
Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation
Authors: Fareed, J Walenga, JM Hoppensteadt, DA Jeske, WP Lietz, H Ahmad, S Callas, D Messmore, HL Haas, S
Citation: J. Fareed et al., Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation, SEM THROMB, 25, 1999, pp. 37-42
Laboratory tests for the diagnosis of heparin-induced thrombocytopenia
Authors: Walenga, JM Jeske, WP Fasanella, AR Wood, JJ Bakhos, M
Citation: Jm. Walenga et al., Laboratory tests for the diagnosis of heparin-induced thrombocytopenia, SEM THROMB, 25, 1999, pp. 43-49
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis ofheparin-induced thrombocytopenia
Authors: Izban, KF Lietz, HW Hoppensteadt, DA Jeske, WP Fareed, J Bakhos, M Walenga, JM
Citation: Kf. Izban et al., Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis ofheparin-induced thrombocytopenia, SEM THROMB, 25, 1999, pp. 51-56
Coagulation laboratory testing in patients treated with argatroban
Authors: Walenga, JM Fasanella, AR Iqbal, O Hoppensteadt, DA Ahmad, S Wallis, DE Bakhos, M
Citation: Jm. Walenga et al., Coagulation laboratory testing in patients treated with argatroban, SEM THROMB, 25, 1999, pp. 61-66
Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications
Authors: Haas, S Walenga, JM Jeske, WP Fareed, J
Citation: S. Haas et al., Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications, SEM THROMB, 25, 1999, pp. 67-75
Clinical experience with combined treatment of thrombin inhibitors and GPIIb IIIa inhibitors in patients with HIT
Authors: Walenga, JM Jeske, WP Wallis, DE Bakhos, M Lewis, BE Leya, F Fareed, J
Citation: Jm. Walenga et al., Clinical experience with combined treatment of thrombin inhibitors and GPIIb IIIa inhibitors in patients with HIT, SEM THROMB, 25, 1999, pp. 77-81
Laboratory monitoring of pentasaccharide in a dog model of hemodialysis
Authors: Hoppensteadt, DA Jeske, WP Walenga, JM Fu, KD Yang, LH Ing, TS Herbert, JM Fareed, J
Citation: Da. Hoppensteadt et al., Laboratory monitoring of pentasaccharide in a dog model of hemodialysis, THROMB RES, 96(2), 1999, pp. 115-124
Heparin-induced thrombocytopenia: Pathophysiology and clinical management - Introduction
Authors: Walenga, JM
Citation: Jm. Walenga, Heparin-induced thrombocytopenia: Pathophysiology and clinical management - Introduction, SEM HEMATOL, 36(1), 1999, pp. 1-1
Laboratory tests for heparin-induced thrombocytopenia: A multicenter study
Authors: Walenga, JM Jeske, WP Wood, JJ Ahmad, S Lewis, BE Bakhos, M
Citation: Jm. Walenga et al., Laboratory tests for heparin-induced thrombocytopenia: A multicenter study, SEM HEMATOL, 36(1), 1999, pp. 22-28
Antithrombin agents as anticoagulants and antithrombotics: Implications indrug development
Authors: Fareed, J Callas, D Hoppensteadt, DA Lewis, BE Bick, RL Walenga, JM
Citation: J. Fareed et al., Antithrombin agents as anticoagulants and antithrombotics: Implications indrug development, SEM HEMATOL, 36(1), 1999, pp. 42-56
Risultati: 1-25 | 26-50 |